Vivance
PrivateLast Round
Series B
Sep 13, 2023
Total Funding Raised
$71.2M
Momentum Score
50 /100
Company Overview
Vivance is a healthcare company specializing in ultraportable dialysis devices that utilize sorbent technology to regenerate used dialysis fluid, offering patients a more convenient and less burdensome treatment for chronic kidney disease management.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials, Health IoT, Medical AI, Patient Engagement
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivance Comps
Public and private peers based on sector, stage, and business model.
Vivance Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 13, 2023 | ||||
| Series A Extension | Dec 12, 2019 | ||||
| Series A | Dec 1, 2016 |
Key People
Founding team and executive leadership
Vivance Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SEEDS Capital | Series A Extension |
| Vickers Venture Partners | Series A Extension, Series B |
| Lion X Ventures | Series B |
Vivance Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Vivance's valuation, stock price, and market status.
